AstraZeneca plc with ticker (LON:AZN) now has a potential upside of 38.4% according to JP Morgan.
AZN.L
JP Morgan set a target price of 14,000 GBX for the company, which when compared to the AstraZeneca plc share price of 10,114 GBX at opening today (15/11/2024) indicates a potential upside of 38.4%. Trading has ranged between 9,461 (52 week low) and 13,388 (52 week high) with an average of 2,372,380 shares exchanging hands daily. The market capitalisation at the time of writing is £156,025,898,582.
AstraZeneca PLC is a science-led biopharmaceutical company. It discovers, develops, and commercializes prescription medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal and metabolism, respiratory and immunology and vaccines and immune therapies. Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Zoladex, Faslodex and others. Its rare diseases products include Soliris, Ultomiris, Strensiq and Kanuma. Its biopharmaceuticals products include Farxiga, Crestor, Breztri and others. Its investigational vaccine candidate IVX-A12, which targets both respiratory syncytial virus and human metapneumovirus. Its oncology candidate includes FPI-2265 targeting prostate specific membrane antigen for metastatic castration resistant prostate cancer, which is in a Phase II trial. It also discovers, develops, and manufactures T-cell receptor therapies. Its Eneboparatide is an investigational therapeutic peptide.
AstraZeneca plc 38.4% potential upside indicated by JP Morgan
- Written by: Charlotte Edwards
Latest Company News
AstraZeneca will invest $2bn in Summit Therapeutics to accelerate the development of ivonescimab and expand its potential use in combination with ADCs. The companies will also collaborate on trials combining ivonescimab with Sone-Ve across gastrointestinal cancers.
The European Commission has approved AstraZeneca’s Trixeo Aerosphere as a maintenance treatment for patients aged 12 and older whose asthma is inadequately controlled with medium-dose ICS/LABA therapy.
The EMA’s CHMP has recommended Klygefa (gefurulimab) for approval as an add-on treatment for adults with AChR antibody-positive generalised myasthenia gravis, based on Phase III PREVAIL trial results.
The FDA has approved Etcamah (camizestrant) with a CDK4/6 inhibitor for HR-positive, HER2-negative advanced breast cancer after detection of an emerging ESR1 mutation, based on Phase III SERENA-6 results showing a 56% reduction in the risk of disease progression or death.
AstraZeneca has reported positive Phase III CROSSING trial results for Tezspire in eosinophilic oesophagitis, with benefits sustained to week 52.
AstraZeneca has priced four tranches of Eurobonds totalling €2.55 billion, with closing expected on 1 September 2026.
